Overview

NeuClone’s business is in genetic engineering with a focus on biogenerics – the generic biopharmaceutical industry. One of the major determinants for a competitive advantage in the biogenerics market will be in the strength of brand and integrity of the process science behind the therapeutic. 

NeuClone is founded by expert scientists and engineers having global reputations in cell biology, molecular genetics and process engineering for creating industrial cell lines capable of high productivity and biological activity. 

NeuClone’s cell lines are licensed to manufacturers of biological drugs, which attract upfront and royalty payments on the sale of protein products produced from our cell lines. 

Business Opportunities (i.e Corporate Alliances/Partnerships)

The key market targeted by NeuClone is the growing market for protein therapeutic drugs produced using mammalian cell culture. NeuClone licenses its cell lines to biogeneric manufacturers in countries that have growing biogeneric markets; primarily, in Asia, South America and Latin America. NeuClone intends to become a global provider of industrial cell lines for the manufacturer of recombinant proteins including biogenerics.

We are seeking local biotech companies and research institutes that require genetic engineering technology to generate recombinant mammalian cell lines for the production of protein therapeutics for the healthcare sector.

Technology/Products and Services Description

NeuClone is developing a selection of recombinant mammalian cell lines expressing high-value therapeutic proteins and destined for commercial manufacture. Cell lines produce generic versions of authentic proteins for which patents have expired such as human growth hormone, interferons, erythropoietin, colony stimulating factors and monoclonal antibodies.